“…Major pharmaceutical companies such as Bayer (BAY1143572/ Atuveciclib), Pfizer (PHA-767491), Eli Lilly (LY2857785), and AstraZeneca (AZ5576) have developed their own CDK9 inhibitors which are being tested in pre-clinical and clinical studies of many disease models including B-or T-Cell Leukemia/Lymphoma, esophageal adenocarcinoma, acute myelogenous leukemia, primary peritoneal carcinoma, chronic lymphocytic leukemia, relapsed multiple myeloma, non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute biphenotypic leukemias, advanced breast cancer, non-small cell lung cancer, solid advanced tumors, etc. [244][245][246][247][248][249]. Including Alvocidib, there are several CDK9 inhibitors including Dinaciclib, Seliciclib, Atuveciclib, Voruciclib, and SNS-032, which are being examined in clinical trials for treatments of these diseases [250][251][252][253] (Table 3).…”